Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment

BACKGROUND: Clozapine is the only licensed medication for treatment-resistant schizophrenia. The metabolism of clozapine is affected by multiple pharmacokinetic interactions, so the co-administration of adjunct medications can have a significant clinical effect. The anti- tuberculosis medication rif...

Descripción completa

Detalles Bibliográficos
Autores principales: Gee, Siobhan, Dixon, Thomas, Docherty, Mary, Shergill, Sukhwinder S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542109/
https://www.ncbi.nlm.nih.gov/pubmed/26265348
http://dx.doi.org/10.1186/s12888-015-0536-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542109/
https://www.ncbi.nlm.nih.gov/pubmed/26265348
http://dx.doi.org/10.1186/s12888-015-0536-4

Ejemplares similares